Source: International Congress 2016 – Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anna Goljan Geremek (Warsaw, Poland), Anna Goljan Geremek, Monika Czystowska, Agnieszka Skoczylas, Elzbieta Puscinska, Michal Bednarek, Adam Nowinski, Pawel Sliwinski. TNF-α polymorphism as a prognostic marker for MTX efficacy in progressive pulmonary sarcoidosis. Eur Respir J 2016; 48: Suppl. 60, 817

Member's Comments

No comment yet.

Related content which might interest you: Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Are there any predictors of MTX response in progressive pulmonary sarcoidosis? Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Proinflammatory cytokine gene polymorphisms in the prediction of clinical course in sarcoidosis patients Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Incidence, clinical manifestations and prognosis of cardiac sarcoidosis in patients with pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Does the HLA-DRB1-genotype influence the course of disease in Danish sarcoidosis patients? Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Genetic analysis of ethnicity of sarcoidosis patients in the Netherlands Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Sarcoidosis Source: Respipedia Article Year: 2017 Variants of the clinical course of familial pulmonary sarcoidosis Source: International Congress 2019 – Sarcoidosis: a multifaceted disease that is difficult to manage Year: 2019 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Association between adipokines, inflammatory markers and systemic manifestations in chronic obstructive pulmonary disease (COPD) patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Comparative role of serum cathepsin S concentrations for differential diagnosis of sarcoidosis from other lung diseases Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Clinical phenotypes and outcomes of pulmonary veno-occlusive disease in carriers of bi-allelic EIF2AK4 mutations Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy Source: Annual Congress 2013 –Sarcoidosis Year: 2013